Skip to main content

Table 2 Per-country analysis of DCR/SIF characteristics (country vs. other; chi2 test, if not stated otherwise)

From: Drug consumption rooms (DCRs) as a setting to address hepatitis C – findings from an international online survey

  Netherlands
n = 8
Switzerland
n = 7
Germany
n = 17
Spain
n = 9
Remaining countries
n = 8
Total
n = 49
proportion (%) proportion (%) proportion (%) proportion (%) proportion (%) proportion (%)
Operational
 Operated by the government 4/8(50.0) 3/6(40.0) 2/14(14.3*) 4/9(44.4) 5/8(62.5) 18/45(40.0)
 Funding from local government 8/8(100.0*) 3/5(60.0) 11/15(73.3) 6/9(66.7) 4/8(50.0) 32/45(71.1)
 Co-located with another program 5/8(62.5) 4/6(66.7) 10/15(66.7) 3/9(33.3) 4/8(50.0) 26/46(56.5)
 Stand-alone facility with other services nearby 0/8(0.0*) 2/6(33.3) 3/15(20.0) 4/9(44.4) 5/8(62.5*) 14/46(30.4)
Staff-Related
 Employing a nurse 4/8(50.0*) 6/6(100.0) 11/15(73.3) 8/9(88.9) 8/8(100.0) 37/46(80.4)
 Employing a medical doctor 3/8(37.5) 0/6(0.0*) 7/15(46.7) 4/9(44.4) 6/8(75.0*) 20/46(43.5)
 Employing peer workers 3/8(37.5) 2/6(33.3) 1/15(6.7) 1/9(11.1) 3/8(37.5) 10/46(21.7)
 Number of paid staff on average day - n (mean country / other - t-test) 6(3/8*) 6(6/8) 13(8/7) 9(7/7) 8(11/7*) 42(7)
Client-Related
 Number of attendees per day - n (mean country / other - t-test) 7(16/130*) 5(158/100) 12(106/108) 8(109/107) 4(206/95*) 36(108)
 % of clients tested for HCV - n (mean country / other - t-test) 5(59/72) 5(78/69) 14(77/67) 9(77/69) 8(54/75) 41(71)
 % of clients estimated as HCV positive - n (mean country / other - t-test) 5(33/61**) 5(51/59) 15(57/58) 8(69/55*) 8(67/55) 41(58)
Service-Related
 Naloxone onsite 1/8(12.5) 1/6(16.7) 4/15(26.7) 8/9(88.9***) 3/8(37.5) 17/46(37.0)
 HIV counselling onsite 1/8(12.5***) 3/6(50.0) 14/15(93.3*) 8/9(88.9) 6/8(75.0) 32/46(69.6)
 HIV testing onsite 0/8(0.0***) 2/6(33.3) 9/15(60.0) 8/9(88.9*) 6/8(75.0) 25/46(54.4)
 OST onsite 2/8(25.0) 0/6(0.0) 5/15(33.3) 3/9(33.3) 1/8(12.5) 11/46(23.9)
 HBV vaccination onsite 1/8(12.5) 1/6(16.7) 7/15(46.7) 6/9(66.7) 4/8(50.0) 19/46(41.3)
 Number of spaces for drug use - n (mean country / other - t-test) 7(10/12) 5(26/10***) 15(11/12) 8(5/13*) 6(13/12) 41(12)
HCV-Related services
 HCV testing onsite 2/7(28.6*) 4/7(57.1) 12/17(70.6) 8/9(88.9) 6/8(75.0) 32/48(66.7)
 Liver monitoring or disease management onsite 2/7(28.6) 2/6(33.3) 11/17(64.7) 5/8(62.5) 5/8(62.5) 25/46(54.4)
 HCV treatment onsite  or plan to provide in the future 1/7(14.3) 0/6(0.0) 5/17(29.4) 1/9(11.1) 3/8(37.5) 10/47(21.3)
  1. *statistically significant difference (country group vs. all other countries) on p < 0.05 level; **statistically significant difference on p < 0.01 level; ***statistically significant difference on p = 0.00 level